The dysfunction of central cholinergic systems has been apparent in patients suffering from dementia (1, 2) . In addition, the cholinesterase inhibitors are effective in treating Alzheimer's disease (3 6) and in experimental animals (7, 8) . Therefore, numerous animal models used in the search for potential nootropic agents are related to the modulation of acetylcholine systems (9, 10) . Recent studies indicated that the monoamines and the second messengers including adenosine 3'5'-cyclic monophos phate (cAMP) play critical roles in learning and memory (11) . A relationship between the monoaminergic system and the cholinergic pathway has also been suggested (12) (13) (14) . In fact, monoaminergic agents such as mono amine oxidase inhibitors, which have an anti-depressive effect, improved cognitive function in animal models (15, 16) . The hypothesis has been put forward that cognitive disruption might arise not only from a dysfunction of the cholinergic system, but also from a dysfunction of central monoaminergic systems, including neuronal second mes senger systems (17, 18) .
Rolipram is an inhibitor that is selective for the Cat /calmodulin-independent and cAMP-specific isozyme of phosphodiesterase (PDE4) (19) . It has been demonstrated to be effective against depressive disorders in clinics and in experimental animals (20) (21) (22) and has different effects on the monoaminergic system compared with those of the known monoaminergic agents. It has been suggested that rolipram has an accelerating effect on noradrenergic transmission by both an enhancement of noradrenergic turnover presynaptically (23) and an inhibition of cAMP degradation postsynaptically (24) . However, the effect of rolipram on learning and memory is as yet unknown. In the present study, to examine the differences in the pharmacological properties of rolipram and its stereoisomers, we investigated 1) whether (±)-rolipram and its isomers could attenuate the scopolamine-induced deficits of learning and memory in rats by using a radial arm maze and a passive avoidance test and 2) whether these agents would potentiate the oxotremorine-induced tremors in mice and have a stimulating effect on the cholinergic system. 
MATERIALS AND METHODS

Animals
Male Wistar rats weighing 200-250 g and male ddY mice weighing 20-25 g were obtained from the Kyu-Do Co. (Saga); they were housed in groups of 4 to 5 per cage, in a room with a controlled temperature of 23±2 C and relative humidity of 60± 10010 with lights on from 7:00 to 19:00. The rats used in the 8-arm radial maze task were placed under restricted food intake (10-12 g/day) (CE-2; Clea Japan, Tokyo). Their body weights were maintained at approximately 80% of the free feeding level during the experimental period. Water was freely available in their home cages. Animal care and the experimental pro cedures were based on the regulations dictated by the Animal Care and Use Committee at Fukuoka University.
Drugs
The following drugs were used: Scopolamine hydrobromide and oxotremorine hydrochloride (Sigma Chemical Co., St. Louis, MO, USA). Scopolamine and oxotremorine were dissolved in saline (0.9010 NaCI in dis tilled water). (±)-Rolipram ((±)-4-(3-cyclopentyloxy-4 methoxyphenyl)-2-pyrrolidinone, Fig. 1 ) and its optical isomers were from Schering AG (Berlin, Germany); they were suspended in 0.5010 carboxymethylcellulose (Sigma).
Measurement of radial arm maze performance
The behavioral testing was conducted on an 8-arm radial maze (Neuroscience Co., Tokyo), a modification of the maze originally developed by Olton and Samuelson (25) . It was elevated 50 cm from the floor. The maze con sisted of a central platform 24 cm in diameter, with eight arms extending radially. Each arm was 50 cm in length, 10 cm in width and 50 cm in height with transparent plas tic side walls. Food cups for the reinforcers were located near the end of each arm. The maze was located in a room containing many extra-maze visual cues. For the behav ioral analysis, an image motion analyzer, AXIS-30 (Neu roscience), was used to quantify the task performance of rats in the maze. The high speed analyzer had an auto matic tracking system which was able to track each rat's movement in the maze with a CCD camera linked to a personal computer, which then analyzed the movement in real time and assessed the length of the route, frequency of arm visits, velocity of walking and time required to accomplish the task.
At first, the test animals were habituated to the ap paratus for a 10-min period; this was done 3 times a day at an interval of more than 1 hr. In these periods, the animal was allowed to move freely within the maze and to get pellets. The habituation was carried out for 3 con secutive days before the training period. For each training session, the test animal was placed in a circular plastic ring on the platform at the middle of the maze. Then, after 1 min, the ring was lifted, and the test animal was al lowed to move freely in the maze. The session continued until the test animal entered all eight arms or 10 min had elapsed. The performance of the test animal in each training session was assessed by two parameters: the number of correct choices of the first 8 arms chosen and the number of errors, that was defined as choosing an arm that had already been visited. If a test animal reached the criterion of more than 7 correct choices and less than 1 error in 3 successive sessions, scopolamine (0.5 mg/kg, i.p.) was administered to the test animal 30 min prior to the test. Rolipram or an isomer was administered p.o. 30 min before the test animals were treated with scopolamine (3 9 rats per group). Test performance was also assessed with the above two parameters. Spatial cognition in the affected animals was considered to be improved when the drug-state rats made significantly increased correct choices and significantly decreased errors as compared with untreated affected animals.
Measurement of passive avoidance response
The experiments were carried out using a step-through type passive avoidance apparatus (Neuroscience) consist ing of an illuminated compartment (20 x 10 x 12 cm) with a 6 W tungsten lamp and a dark compartment The experiments consisted of training (acquisition) and retention tests. In the training session, each rat was placed in the illuminated compartment and allowed 1 min for habituation. The guillotine door was then opened. The guillotine door was closed immediately when the animal entered the dark compartment, and 10 sec later, an elec tric shock was delivered through the grid floor. In the retention test, 24 hr after the training test, each animal was again placed in the illuminated compartment, and its latency (step-through latency) to enter the dark compart ment was measured (the cut-off time was 600 sec). Scopolamine at a dose of 3 mg/kg was used for this ex periment, because scopolamine at 0.5 mg/kg which is a disruptive dose of the radial maze task was not impaired in the retention of the passive avoidance task. Scopol amine was injected i.p. 30 min before the retention test, and rolipram or an optical isomer was administered p.o. Rolipram or an optical isomer was administered orally 50 min before the injection of oxotremorine (10 mice per group). Observation of the tremors was made at 5-min intervals starting 30 min after the oxotremorine treat ment, and the intensity of tremors was determined as the mean of the total score during a 30-min test.
Statistical analyses
The results of the radial maze task and the oxotremo rine tremor were expressed as means±S.E.M., and medians and interquartile ranges were calculated for the passive avoidance task. The following statistical analyses were made to assess the differences in values between groups: Wilcoxon's rank sum test for the 8-arm radial maze task and oxotremorine-induced tremors and the Mann-Whitney U-test for the passive avoidance task. 
RESULTS
Effects of rolipram and its optical isomers on scopol amine-induced deficits of spatial cognition in the radial arm maze task Figure 2 shows the effects of rolipram and its isomers on the radial arm maze performance in rats. After scopolamine (0.5 mg/kg) was injected to the test animals that had acquired spatial cognition, the numbers of cor rect choices were significantly decreased and the number of errors were significantly increased, indicating that the spatial cognition was impaired. Effects of rolipram and its isomers on the oxotremorine induced tremors Figure 4 shows the effects of rolipram and its isomers on oxotremorine-induced tremors in mice. Oxotremorine 
DISCUSSION
It is well-known that brain cholinergic hypofunction can cause dementia such as memory loss and disorienta tion in cerebrovascular or Alzheimer's disease (3, 4) . An acetylcholinesterase inhibitor, tetrahydro-aminoacridine (THA), has been shown to improve these symptoms in patients with dementia (5-7). Based on these findings concerning the cholinergic systems, scopolamine, a mus carinic receptor antagonist, has been useful for the evalu ation of the effects of drugs on learning and memory deficits in animals and humans (9, 10) . We also have reported that scopolamine impaired the performance in the radial maze task and passive avoidance task, and cholinergic enhancers such as physostigmine and THA improved the deficits of memory performance (26) . Moreover, it has been reported that scopolamine decreased not only the acetylcholine (ACh) contents but also the noradrenaline (NA) contents in the frontal cortex (FC), and non-cholinergic drugs such as low-dose aman tadine or L-threo-DOPS also improved the scopolamine induced deficits of spatial cognition and reversed the decrease in the NA contents of the FC (27, 28) . These results suggest that the scopolamine-induced deficits of spatial cognition in rats originate from the dysfunction of multiple neurotransmitter.
In the present study, to examine the pharmacological properties of rolipram, we investigated whether rolipram and its isomers attenuate scopolamine-induced learning and memory deficits in rats. Rats treated with rolipram or one of its isomers showed improvement in the scopol amine-induced deficits in the radial arm maze task and passive avoidance task. In the maze task, (± at their mini mum effective dose. Furthermore, the effective range of (-) and (±)-rolipram on the passive avoidance task is also approximately 200 times more potent than that of (+)-rolipram. Although the exact reason why the racemic isomer's effects is still unknown, (-) or (±)-rolipram would seem to be good candidates for the treatment of cholinergic deficiencies. Therefore, comparing these two drugs, (±)-rolipram has a wide range of efficacy in scopolamine-induced deficit of spatial cognition. These results confirmed the previous finding using a discrimina tion task that the rank order potency of each of the rolipram stereoisomers as the discriminative stimulus was ( )-rolipram = (± )-rolipram > (+ )-rolipram, although the potency for both tasks was different from the IC50 for inhibiting PDE4. Moreover, several PDE inhibitors were found to substitute for (±)-rolipram's cue, their potencies in the discrimination task were reported to be well-correlated with their potency to displace [3H] rolipram from forebrain binding sites in vivo (29) . It was also reported that the action of (-)-rolipram is very po tent in increasing cAMP levels in rat brain (30) . These results suggest that the wide ameliorating efficacy of (±) rolipram might be useful for clinical use.
Recent pharmacological studies demonstrated that cAMP enhanced hippocampal long-term potentiation (31, 32) , which is widely regarded as a possible candidate for a synaptic basis of learning and memory in the central nervous system (33) . These findings suggested that the enhancement of signal trasduction via adenylate cyclase in the hippocampus may play a major role in learning and memory (11) . From these facts, present findings that (±) rolipram attenuates the scopolamine-induced deficits of learning and memory may result from an increase in cAMP via the inhibition of PDE4. Therefore, to investigate whether (± )-rolipram had a direct cholinergic stimulating effect, we examined the effect of (± )-rolipram and its isomers on oxotremorine-induced tremor. Oxotremorine induced tremor in mice has been reported to be a useful model for the initial identification of drugs with the cen tral cholinergic potency because these drugs have a direct stimulating effect on central muscarinic receptors (27) . The present results showed that ( ) and (± )-rolipram significantly potentiated the oxotremorine-induced tremor at doses that appeared to improve on the maze task. In addition, analogues of cAMP have been reported to promote the activity of cholinergic neurons and to potentiate acetylcholine responses (34, 35) . However, it is also reported that rolipram enhances NA turnover presynaptically and accumulates cAMP by inhibiting PDE postsynaptically (36) . Since NA-related drugs can attenuate the scopolamine-induced deficits of learning and memory, our results suggest that (±)-rolipram pos sesses a stimulating effect on the central monoaminergic systems. From these results it is considered that (± ) rolipram may increase cAMP via the inhibition of PDE4 and secondarily activate the cholinergic and noradren ergic systems. It is necessary to consider that rolipram affects other systems that are disrupted by scopolamine via an increase in cAMP. Indeed, we already reported that many cognitive enhancers can improve scoplamine induced disruption of spatial cognition in rats without activating directly the cholinergic and noradrenergic sys tems (26, 27) .
In conclusion, the results showed that the treatments with (±)-rolipram attenuate the scopolamine-induced 
